Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2023-03-27 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Patients dosed in VLP Peanut PROTECT trial
Regulatory Filings Classification · 98% confidence The document is clearly identified as an 'RNS Number' announcement from 'Allergy Therapeutics PLC' dated March 27, 2023. It announces a specific corporate event: the commencement of dosing in the Phase I PROTECT trial for a vaccine candidate. The text concludes with standard disclaimers about RNS being the news service of the London Stock Exchange and an 'END' marker. This format is characteristic of a general regulatory news service announcement that does not fit into more specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS). Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement fallback.
2023-03-27 English
Block Listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'Block Listing Interim Review' for the 'Allergy Therapeutics plc 2013 Long Term Incentive Plan,' reporting on the balance of unallotted securities over a specific period (August 2022 to February 2023). This is a routine regulatory disclosure related to the listing of shares, which fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). Given the explicit mention of RNS and the nature of the filing (a review of listed securities), RNS is the most appropriate classification.
2023-03-08 English
PDMR Dealing
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7437R' and contains extensive regulatory formatting typical of announcements made via the Regulatory News Service (RNS). The content explicitly details 'PDMR Dealing' (Persons Discharging Managerial Responsibilities) transactions concerning the 'Issue of 33,333,332 Warrants' to parties associated with Non-Executive Directors. This falls under insider trading/director dealing disclosure requirements. The specific category for reporting personal share transactions by directors and executives is 'Director's Dealing' (Code: DIRS). Although it is distributed via RNS, the specific content dictates the DIRS classification over the general RNS fallback.
2023-03-03 English
Result of AGM
AGM Information Classification · 99% confidence The document explicitly states it is announcing the 'Result of Annual General Meeting' held on February 7, 2023. It details that 'all resolutions proposed at the 2022 Annual General Meeting ("AGM") held today were duly passed by shareholders' and provides a table outlining the results of the proxy votes for each resolution (Ordinary and Special). This content directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). While it relates to an AGM, the core content is the voting result declaration, not the AGM presentation materials (AGM-R) or the proxy solicitation materials (PSI).
2023-02-07 English
Half-Year Trading Update 2023
Earnings Release Classification · 99% confidence The document is titled 'Half-Year Trading Update 2023' and provides key financial figures (revenue, cash balance) for the six months ended 31 December 2022. This content aligns perfectly with the definition of an Interim/Quarterly Report (IR). Although it is a brief update, it contains specific financial metrics for the period, making it more than just a 'Report Publication Announcement' (RPA). The presence of the RNS Number and the closing statement about RNS being the Primary Information Provider confirms it is a regulatory announcement, but the core content is the interim financial performance summary. Since 'IR' covers comprehensive reports for shorter periods, this trading update fits best under this category, as it summarizes the period's performance. H1 2023
2023-01-20 English
NOTICE OF 2022 ANNUAL GENERAL MEETING
AGM Information Classification · 98% confidence The document explicitly states 'NOTICE OF 2022 ANNUAL GENERAL MEETING' and mentions that Allergy Therapeutics plc 'has today published it's Notice of 2022 Annual General Meeting.' This directly relates to the AGM. However, the document itself is a short regulatory announcement (RNS Number: 7383M) whose primary function is to announce the publication of the Notice, rather than being the full AGM presentation or materials. According to Rule 2, if a document is short and announces the publication of another document, it should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Since the content is a formal announcement of a specific corporate event notice, and the definition for AGM-R is 'Presentations and materials shared during the Annual General Meeting (AGM)', this short notice announcing the availability of the AGM notice is best classified as an RPA or RNS. Given the specific nature of announcing the publication of a formal notice, RPA is slightly more precise than the general RNS fallback, although RNS is also plausible. I will select RPA as it announces the publication of a document.
2023-01-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.